Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP ST-elevation myocardial infarction (STEMI) Registry of the European Society of Cardiology
Authors' conclusion
The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality.
Study context
- Population
- Hospitalized STEMI patients with symptom onset <24 h in European Society of Cardiology (ESC) member and affiliated countries
- Participants
- 11,462 patients
- Exposure
- Primary percutaneous coronary intervention (PCI) vs fibrinolysis vs no reperfusion therapy
- Outcome
- Use of reperfusion therapy and adherence to ESC guidelines
Methodological detailsmulticentre, 196 centres, 29 countries
- Multicentre
- 196 centres, 29 countries
Main finding
As reported in the abstract
Use of reperfusion therapy
| Group | Value | Country range |
|---|---|---|
| Primary PCI | 72.2% | 0-100% |
| Fibrinolysis | 18.8% | 0-100% |
| No reperfusion | 9.0% | 0-75% |
Value
Primary PCI72.2%
Fibrinolysis18.8%
No reperfusion9.0%
Country range
Primary PCI0-100%
Fibrinolysis0-100%
No reperfusion0-75%
- Quality indicator: reperfusion therapy in STEMI <12 h (region range 84.8-97.5%)
- 92.7%
- Quality indicator: timely reperfusion (region range 37.1-70.1%)
- 54.4%
Observational data: associations, not effects.
Further findings
In-hospital all-cause mortality
- In-hospital all-cause mortality — Overall in-hospital mortality (country range 2.5-5.9%)
- 4.4%
Original publication
Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. Eur Heart J. Published 14 August 2021. doi:10.
Summarised from the published abstract; every number is checked against it